All News

The ROCK-2–targeting agent belumosudil is now approved by the FDA to treat adult and pediatric patients with chronic graft-versus-host disease after 2 prior lines of therapy.

Foundation Medicine announced the expanded indication for FoundationOne Liquid CDx as a companion diagnostic to identify MET exon 14 skipping mutations in metastatic non–small cell lung cancer.

Findings from the OCTOPUS Consortium of trial data indicated that weight-based chemotherapy dosing may improve outcomes for obese patients with colorectal cancer.

CancerNetwork® sat down with Richard D. Kim, MD, of the Moffitt Cancer Center at the 2021 ASCO Annual Meeting to talk about the many ways oncologists can approach treating hepatocellular carcinoma with combination regimens.

Moreau discussed conclusions drawn from part 2 of the CASSIOPEIA trial and the need for further follow-up with bortezomib, thalidomide and dexamethasone plus maintenance daratumumab in newly diagnosed multiple myeloma.

Men diagnosed with mCPRC who are treated with 117Lu-PSMA may be assessed using nomograms to help predict outcomes.

Data in patients with colorectal cancer indicates that the Signatera MRD test may help guide treatment decisions in patients with resectable disease.

Adverse effects in patients taking tazemetostat were manageable, with most patients reporting low-grade fatigue, pain, and nausea.

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Adjuvant radiation therapy, when compared with early salvage radiation therapy, reduced the risk of all-cause mortality for patients with adverse pathology at radical prostatectomy.

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

Julian Adams, PhD, discusses the potential of Omidubicel for patients with hematologic cancers such as lymphomas and leukemias.

More elderly, frail patients with colorectal cancer were able to complete adjuvant chemotherapy following geriatric intervention.

Robert A. Figlin, MD, details how his institution, Cedars-Sinai Cancer, is aiming to fully understand the cancer journey for those with genitourinary malignancies.

An expert in treating breast cancer discusses potential therapy options for patients with HER2-mutant.

Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer.

The FDA approved the combination of daratumumab and hyaluronidase-fihj plus pomalidomide/dexamethasone as therapy for certain patients with pretreated multiple myeloma.

At ASCO 2021, Tanios S. Bekaii-Saab, MD, talked about some of his research in patients with IDH1/2–positive cholangiocarcinoma presented at the meeting.

An oncology pharmacist details the unique mechanism of active of tazemetostat in the treatment of follicular lymphoma.

At ASCO 2021, Shaji Kumar, MD, talked about the impact of adding daratumumab maintenance to therapy for patients with newly diagnosed multiple myeloma in the CASSIOPEIA trial.

Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.

During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.

Enfortumab vedotin-ejfv has been approved by the FDA for locally advanced or metastatic urothelial cancer.

This year’s Annual Report to the Nation on the Status of Cancer highlights trends in cancer incidence and mortality overall and in key patient subgroups.

Despite some delayed immune responses, the Pfizer COVID-19 vaccine appears safe and effective in patients with cancer who are receiving treatment for their disease.

Results from the phase 3 KEYNOTE-811 study indicated that pembrolizumab and trastuzumab plus chemotherapy yielded robust, long-lasting responses in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.